In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history Excluding milestone ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from ...

Samsung Bioepis, a subsidiary of Samsung Epis Holdings, achieved its highest annual sales performance last year. According to ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization ...

Dr Reddy's Laboratories Ltd (RDY) reports steady revenue growth driven by emerging markets and strategic collaborations, ...

This past year contained a number of significant developments in litigation involving biologics and biosimilars. The following is a recap of the ...

Amneal Pharmaceuticals re c eived FDA approval for two denosumab biosimilars referencing Prolia and Xgeva. The approval, announced Dec. 22, covers Boncresa (denosumab-mobz) and Oziltus (denosumab-mobz ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Washington — The Trump administration plans to halt billions of dollars in federal funding for social services programs in five states led by Democrats following allegations of fraud, a Department of ...

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, ...